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The production of platelet-actlvatmg factor (PAF) m A23187-sttmulated human polymorphonuclear leukocytes was markedly Increased m the pres- 
ence of 5 mM acetoacetate and D-hydroxybutyrate Such an augmentanon was observed even at 500 PM but not at 50 PM The augmented produc- 
uon of PAF by acetoacetate was also observed m the presence of autologous erum and was most promment m the case of opsomzed zymosan- 
sttmulatton rather than A23187-sttmulatton These observattons uggest hat increased levels of acetoacetate and /J-hydroxybutyrate m blood may 
lead to the augmented produchon of PAF, which would amplify the various PAF-mediated btologtcal reacttons 
Platelet-actrvatmg factor, Polymorphonuclear leukocyte, Ketone body, Acetoacetate, b-Hydroxybutyrate, Acetyl-CoA 
1. INTRODUCTION 
Platelet-activating factor (PAF) is a unique bioactive 
phospholipid which has been identified as I-0-alkyl-2- 
acetyl-sn-glycero-3-phosphocholine (r viewed in [l-3]). 
It causes aggregation, infiltration and degranulation of 
blood cells, increased vascular permeability, smooth 
muscle contraction and hypotension, and is now con- 
sidered to be an important lipid mediator m various in- 
flammatory and allergic reactions [l-3]. 
origin as well as the metabolic regulation of acetyl-CoA 
in PAF-producing cells. It is very important to in- 
vestigate these points in detail in order to better 
understand the modulatory mechanism of PAF pro- 
duction, especially in vivo. 
PAF is known to be synthesized in various tissues 
and cells including inflammatory cells such as polymor- 
phonuclear leukocytes (PMN) upon appropriate 
stimulation. Dual biosynthetic routes for PAF have 
already been proposed [2] and the properties of the en- 
zymes involved in these reactions have also been 
studied by several investigators. The activation of 
acetyl-CoA/ 1 -alkyl-GPC acetyltransferase in 
stimulated cells [4-61 would be favorable for the 
production of PAF through the remodeling of the 
preexisting alkylacyl-GPC in these cells. 
In this study, we examined the effects of ketone 
bodies, which are known to be transporters of acetyl 
units in blood, on the production of PAF in human 
PMN. We found that the addition of pathologically 
significant levels of acetoacetate and fi-hydroxybutyr- 
ate augment the PAF production. The possible rela- 
tionship between these observations and several 
pathological situations is discussed. 
2. MATERIALS AND METHODS 
Despite the accumulating knowledge concerning the 
enzyme activities, however, the mechanism of the 
regulation of PAF synthesis is not fully elucidated yet. 
For example, the control mechanism of the substrate 
availability in living cells still remains quite obscure. In 
fact, little information is available concerning the 
Acetoacettc acid (lithium salt), DL-&hydroxybutyrtc acid (sodium 
salt), DL-Lu-hydroxybutyrrc a td (sodmm salt), y-hydroxybutyrtc actd 
(sodmm salt), cY-ketobutync acid (sodium salt), L-( +)-lacttc acid 
(hthmm salt), pyruvtc acid (sodmm salt), phorbol myrtstate acetate 
(PMA) and zymosan were obtained from Srgma (St. Lotus, MO) 
A23187 was from Calbtochem (La Jolla, CA) Acetic acid (sodium 
salt), acetone and glucose were from Wako Pure Chem Ind. (Osaka, 
Japan) l-O-Hexadecyl-2-acetyl-~n-glycero-3-phosphocholine 
(C16:0-PAF) was purchased from Bachem (Bubendorf, 
Switzerland) A PAF-antagomst, CV3988 was a generous gift from 
Dr Tsushtma, Takeda Chemtcal Inc (Osaka, Japan) 
[‘H]Arachtdomc acrd (192 Ct/mmol) and leukotrrene B4 [‘HIassay 
system were obtained from Amersham (Amersham, UK). 
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Abbrevratrons. PAF, platelet-actuating factor; PMN, polymor- 
phonuclear leukocytes; PMA, phorbol mynstate acetate, LTB4, 
leukotrtene B4, DMSO, drmethyl sulfoxrde 
PMN were isolated from normal human donors as described m [7] 
PMN (2 5 or 5 x lo6 cells) m 0.5 ml or 1 ml of 20 mM Hepes-Hanks 
balanced salt solutron containing 5 6 mM glucose (pH 7 4) were m- 
cubated at 37°C m the presence or absence of 5 mM ketone bodies 
or related compounds. Ten minutes later, PMN were sttmulated by 
the additron of A23187 (final 1 PM), opsomzed zymosan (final 4 
mg/ml) or PMA (final 250 ng/ml) After a further 10 mm mcuba- 
tron, chloroform/methanol (1.2) was added to the mcubatron mrx- 
ture and hptds were extracted by the method of Bhgh and Dyer [8] 
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In some experiments, PMN were incubated m Hepes-Hanks solutton 
contammg 20% autologous serum which had been macttvated by 
heat (56°C for 30 mm) and acid (pH 2.5-3.0 for 15 mm) [9] 
treatments After the sttmulatton with opsomzed zymosan m the 
presence or absence of acetoacetate, cells were spun down (2000 rpm 
for 2 mm) at 4°C Total hptds both from sedtmented cells and from 
supernatants were extracted as described above 
Indtvtdual phosphohprds were separated from each other by TLC 
developed wtth chloroform/methanol/water (40:24.4). The area 
correspondmg to the authentic PAF was scraped off and then ex- 
tracted with chloroform/methanol/water (1 2.0 8) After the extrac- 
tton by the method of Bhgh and Dyer [8], the chloroform layer was 
removed and evaporated to dryness The residue was resuspended m 
Hepes-buffered Tyrode’s solutton (pH 7 4) contammg 0 25% BSA 
The amount of PAF was measured by esttmatmg the aggregatmg ac- 
tivity towards washed rabbrt platelets [lo], using ClB:O-PAF as a 
standard. The aggregation of rabbit platelets by PAF fractton was 
completely mhrbtted by the pretreatment of cells with 8 PM CV3988. 
Furthermore, he phosphohpase AZ treatment of samples abolished 
the actrvtty These results indicate that the aggregation was really due 
to PAF 
3. RESULTS AND DISCUSSION 
Fig.1 shows the effects of ketone bodies and related 
compounds on the production of PAF in A23187-stim- 
ulated human PMN. The addition of 5mM aceto- 
acetate, ,&hydroxybutyrate as well as acetate 
augmented the PAF production by 1.7-1.8 times. In 
contrast, the addition of cu-ketobutyrate, an isomer of 
acetoacetate, or cy- and y-hydroxybutyrate, isomers of 
&hydroxybutyrate, did not affect the PAF production. 
A rather inactive ketone body, acetone, also failed to 
stimulate PAF synthesis, at least at 5 mM. Lactate, 
pyruvate and a high concentration (30 mM) of glucose 
were also found to be ineffective. Furthermore, the ad- 
dition of free arachidonic acid (20:4), in the presence of 
1% human serum albumin, did not affect the PAF syn- 
thesis up to 200 PM and a higher concentration of free 
20:4 showed only an inhibitory effect, at least under 
these experimental conditions (data not shown). 
The dose dependencies of the augmented production 
of PAF by acetoacetate, ,&hydroxybutyrate and acetate 
were next examined. Only a slight acceleration of PAF 
synthesis in A23187-stimulated PMN was observed in 
the presence of 50 ,uM of these 3 compounds (data not 
addltlon (Sri4 
control 
acetoacetate 
6 -hydroxybutyrate 
acetone 
a-ketobutyrate 
a-hydroxybutyrate 
y -hydroxybutyrate 
lactate 
pyruvate 
acetate 
glucose (3GlM) 1 
Ftg.1. Effects of ketone bodies and related compounds on the pro- 
ductton of PAF m A23187-sttmulated human PMN PMN were m- 
cubated with or without these compounds (final 5 mM) for 10 mm 
In the case of glucose, a high concentration (final 30 mM) was 
employed Then, cells were sttmulated with A23187 (1 ,uM) for 10 
mm The amounts of produced PAF were measured as described m 
section 2 The data were expressed as the mean percentages *SD 
from 5 to 6 determmattons *Significantly dtfferent from control 
(P<O OOl), Student’s r-test. 
shown). On the other hand, the amounts of produced 
PAF significantly increased with higher concentrations 
(5OO~M, 5 mM and 20 mM) of these compounds (data 
not shown). The enhancement was maximal at 5 mM in 
each case. This concentration is similar to the concen- 
tration of ketone bodies in which utilization by several 
peripheral tissues reached the plateau [l 11. 
The effects of acetoacetate on the production of PAF 
in PMN stimulated with several stimuli are shown in 
table 1. The addition of acetoacetate did not affect the 
PAF level in control cells. The acceleration was observ- 
ed only for stimulated cells. The amounts of PAF pro- 
duced by the stimulation with A23187, opsonized 
zymosan and PMA, all increased in the presence of 
5 mM acetoacetate. The most prominent augmentation 
was observed in the case of a physiological stimulus, 
opsonized zymosan (the stimulation index was 2.5), 
though the absolute amount of PAF was lower than 
that produced in the case of A23187-stimulation. 
In order to establish the effects of acetoacetate under 
condrtions closer to those in vivo, we next examined the 
effects of acetoacetate in the presence of autologous 
serum. Fig.2 shows the effects of acetoacetate on the 
Table 1 
Strmuh 
Effects of acetoacetate on the productton of PAF m human PMN strmulated wtth several sttmuh 
Acetoacetate (5 mM) Sttmulatton index 
_ + 
pmol/2 5 x lo6 cells/l0 mm 
none 0.05 + 0 01 0 05 + 0.01 10 
DMSO (0 5%) 0.05 + 0 03 0.05 f 0 03 10 
A23187 (1 CM) 299 +17 49.3 f 4 0 1.7 
opsomzed zymosan (4 mg/ml) 123 + 013 3 08 rt 0 48 25 
PMA (250 ng/ml) 037 + 003 071 f 0 19 19 
PMN (2 5 x lo6 cells/O 5 ml or 5 x lo6 cells/ml) were Incubated wtth or wtthout 5 mM acetoacetate for 10 mm Then, cells were sttmulated wtth 
A23187 (1 pM), opsomzed zymosan (4 mg/ml) or PMA (250 ng/ml) for 10 mm A23187 and PMA were diluted with DMSO and then used (the 
fmal concentratron of DMSO m the mcubatton mixture dtd not exceed 0 5%) The values are means &SD from 4 to 5 determmattons 
352 
Volume 258, number 2 FEBS LETTERS December 1989 
pmolef5x106cells 
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I- 
pellet 
+ 
l 
supernatant 
+w l 
Flg.2. Augmented production of PAF m opsomzed zymosan- 
stimulated human PMN by acetoacetate m the presence of 
autologous serum. PMN (5 x lo6 cells/ml) were incubated m 20% 
autologous serum-contammg Hank’s solution for 10 mm with or 
without 5 mM of acetoacetate Then, cells were stimulated wth op- 
somzed zymosan (4 mg/ml) for 10 mm. After the centnfugatlon, 
PAF retamed m cells and that released into the supernatant were ex- 
tracted as described m sectlon 2 The data were expressed as the 
means f SD from four determmatlons *Bgmflcantly different from 
control (P<O.OOl), Student’s &test 
production and release of PAF in opsonized zymosan- 
stimulated PMN in the presence of 20% autologous 
serum. In the absence of serum or serum albumin, 
almost all of the produced PAF was retained in cells 
(data not shown) as previously reported by others 
[9,12]. On the other hand, ca. 20% of PAF was releas- 
ed into the medium in the presence of serum, which is 
in general agreement with the previous observations by 
several investigators [7,9,12,13]. Here we found that 
the addition of a pathological level of acetoacetate 
(5 mM) augmented the PAF production induced by 
opsonized zymosan by 2.3 times even in the presence of 
autologous serum. Both PAF retained m cells and that 
released mto the medium were increased relatively to 
the same degree by the treatment of cells with 
acetoacetate. These observations suggest that the 
augmented production of PAF by ketone bodies may 
have some pathophysiological implications in vivo. 
The possible mvolvement of PAF in the pathogenesis 
of several diseases, such as endotoxin shock, 
anaphylactic shock, nephritis, ischemia and asthma, 
has already been suggested by many investigators [141. 
Thus, the modulation of the biosynthesis of PAF, 
especially in vivo, seems to be a very important prob- 
lem from the pathological viewpoint. In the present in- 
vestigation, we examined the effects of the clinically 
important materials, ketone bodies, which are known 
to be rapidly incorporated and metabolized by 
peripheral tissues to form acetyl-CoA, a precursor for 
the acetyl moiety of PAF. Previously, several m- 
vestigators have shown that the treatments of kidney 
[ 151 and heart [16] with acetoacetate (5 mM) and 
P-hydroxybutyrate (5.5 mM), respectively, markedly 
increased the intracellular level of acetyl-CoA. These 
observations are interesting in view of the availability 
of acetyl-CoA for PAF synthesis, since theKm value of 
the acetyl-CoA:lyso-PAF acetyltransferase for acetyl- 
CoA is considerably higher than the acetyl-CoA level in 
cells (unpublished data). This suggests that the in- 
creased level of intracellular acetyl-CoA would lead to 
the enhanced production of PAF. Concermng this 
possibility, Benveniste and his colleagues [17-191 have 
demonstrated the accelerated synthesis of PAF in 
stimulated macrophages and PMN in the presence of 
acetate and acetyl-CoA. Similar augmentation was 
observed in this study for ketone bodies such as 
acetoacetate and ,&hydroxybutyrate, which are regard- 
ed as important transporters of acetyl units in the 
human body. Although the exact amount of acetyl- 
CoA in PMN has not yet been determined, it is con- 
ceivable that such an augmentation is due to an mcreas- 
ed level of acetyl-CoA within the cells. We confirmed 
that neither the release of [‘H]20:4 nor the production 
of LTB4 was affected by the treatment of cells with 
5 mM acetoacetate (data not shown). 
The blood levels of ketone bodies from normal sub- 
jects are reported to be 44~t 17 ,uM (acetoacetate) and 
59 + 33 pM @hydroxybutyrate) [20]. These concentra- 
tions of ketone bodies, added independently or to- 
gether (data not shown) to PMN, did not change the 
amount of PAF produced by A23187-stimulation 
markedly. On the other hand, the levels of ketone 
bodies are raised dramatrcally (> 1 mM) in several 
pathological situations such as diabetes and starvation, 
in which the lipid catabolism is accelerated [21]. In the 
case of diabetic ketoacidosis, the concentration of 
ketone bodies can be more than 5 mM. The levels of 
ketone bodies even m patients with hyperosmolar non 
S-ketotic coma are often lo-fold higher than the con- 
trol level [21]. These concentrations of ketone bodies 
could be enough to augment the PAF production, as 
shown in this study, suggesting that amplification of 
the PAF-mediated biological responses could take 
place. In this regard, rt 1s interesting to note that the 
platelet aggregation is potentially elevated in diabetic 
patients 122,231. In fact, disseminated intravascular 
coagulation (DIC) is often observed in patients with 
diabetic coma [24,25,26]. The increased platelet aggre- 
gation is also considered to be very important in the 
pathogenesis of microangiopathy. Moreover, endo- 
toxemia, which could be mediated by endogenously 
generated PAF [27,28], is sometimes an important 
complication of diabetes. Further studies are required 
to show whether the increased levels of ketone bodies 
really modify various PAF-induced pathological condi- 
tions in vivo. 
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